MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Myomo Inc

Atvērts

4.29 -7.54

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.22

Max

4.7

Galvenie mērījumi

By Trading Economics

Ienākumi

-5.2M

-260K

Pārdošana

2.9M

12M

EPS

-0.01

Peļņas marža

-2.155

Darbinieki

184

EBITDA

712K

-245K

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+88.78% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

12M

167M

Iepriekšējā atvēršanas cena

11.83

Iepriekšējā slēgšanas cena

4.29

Myomo Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 3. apr. 23:04 UTC

Top Ziņas

JPMorgan Raises Risk of U.S., Global Recession to 60%

2025. g. 3. apr. 22:40 UTC

Galvenie tirgus virzītāji

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

2025. g. 3. apr. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

2025. g. 3. apr. 18:51 UTC

Iegādes, apvienošanās, pārņemšana

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

2025. g. 3. apr. 23:43 UTC

Tirgus saruna

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

2025. g. 3. apr. 23:41 UTC

Tirgus saruna

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

2025. g. 3. apr. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

2025. g. 3. apr. 21:43 UTC

Top Ziņas
Peļņas

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 3. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 3. apr. 20:43 UTC

Tirgus saruna

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

2025. g. 3. apr. 20:34 UTC

Top Ziņas

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

2025. g. 3. apr. 20:23 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 3. apr. 19:55 UTC

Tirgus saruna

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

2025. g. 3. apr. 19:21 UTC

Tirgus saruna

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

2025. g. 3. apr. 19:15 UTC

Tirgus saruna

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:45 UTC

Tirgus saruna

Gold Drops In Tariff Fallout -- Market Talk

2025. g. 3. apr. 18:39 UTC

Tirgus saruna

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

2025. g. 3. apr. 18:38 UTC

Top Ziņas

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

2025. g. 3. apr. 18:30 UTC

Top Ziņas

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

2025. g. 3. apr. 18:20 UTC

Tirgus saruna

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

2025. g. 3. apr. 18:18 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 3. apr. 18:17 UTC

Tirgus saruna

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

2025. g. 3. apr. 18:04 UTC

Tirgus saruna

US Sees More Job Openings in Construction, Transportation -- Market Talk

2025. g. 3. apr. 17:55 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Myomo Inc Prognoze

Cenas mērķis

By TipRanks

88.78% augšup

Prognoze 12 mēnešiem

Vidējais 9.25 USD  88.78%

Augstākais 11 USD

Zemākais 6.75 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myomo Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

5

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.